Investment Review №351. S&P 500 Hits New Highs

Intrepid Potash (IPI) is a U.S.-focused producer of potash and specialty fertilizers, serving primarily the domestic market. The investment case rests on constrained domestic fertilizer supply, rising demand for local sourcing, and a competitive cost structure. Key growth drivers include volume and realization price increases alongside expansion of the specialty fertilizers segment, which holds an established position in the U.S. market. The balance sheet is a further differentiator—following the divestiture of a non-core asset, the company carries a substantial cash position with minimal leverage, enabling capacity expansion and project development without meaningful external financing. The broader backdrop is supportive, underpinned by the strategic imperative to strengthen U.S. domestic food and commodity security. Principal risks include potash price cyclicality, shifts in trade policy, potential recovery in global supply, and execution risk on capex projects. 12-month target price: $45.

Piedmont Realty Trust (PDM) is a REIT focused on Class A office properties across major Sun Belt markets. The investment case is anchored in high portfolio occupancy, rising rental rates, and constrained new supply in quality office submarkets. The primary growth driver is a material volume of executed but not yet fully commenced leases yet to flow through to revenue, alongside the completion of ongoing redevelopment projects expected to lift NOI over the coming years. Additional positives include exposure to high-growth markets—Atlanta, Dallas, and Orlando—where demand for modern office space remains intact, and a debt maturity profile with no significant maturities until 2028, limiting near-term refinancing risk. That said, the stock's substantial rally off its March lows may cap further re-rating potential. Key risks include an economic slowdown weighing on office demand, delays in lease-up at redevelopment assets, and rising tenant improvement and leasing costs. 12-month target price: $11.

TAT Technologies (TATT) is an aerospace solutions provider operating across three segments: aviation component MRO, heat transfer solutions, and equipment trading & leasing. The investment case is underpinned by resilient demand for aviation MRO services, gradual supply chain normalization, and a record order backlog. The primary growth driver is the APU MRO segment, where improving parts availability has enabled the company to complete and ship previously deferred orders. Further upside stems from deepening collaboration with Honeywell, expansion of the distribution and leasing business, and potential operating leverage from infrastructure already in place. That said, Q2 results partly reflect a one-time catch-up effect from backlog execution, with the bulk of new orders expected to convert to revenue gradually over multiple years. Key risks include persistent component supply constraints, rising working capital requirements, elevated parts costs, and FX volatility. 12-month target price: $54.

Sarepta Therapeutics (SRPT) is a biopharmaceutical company focused on rare neuromuscular diseases, including Duchenne muscular dystrophy. The investment case rests on the durability of the commercialized product portfolio—which remains the primary revenue and cash flow engine—alongside the recovery potential of gene therapy ELEVIDYS. The long-term growth driver is a successful return of ELEVIDYS to a sustainable commercial trajectory: rising patient enrollments and treatment center activity point to a gradual demand recovery, though revenue recognition is expected primarily in FY27 given the extended time from enrollment to therapy initiation. An additional catalyst is potential validation of the company's patient risk mitigation strategy, with results expected in 1Q27. In the near term, the base portfolio underpins financial stability over the next one to two years, while pipeline expansion in siRNA-based therapies offers a longer-dated growth optionality. Key risks include limited visibility into the ELEVIDYS demand recovery, gene therapy safety concerns, intensifying competition from emerging treatment modalities, and potential erosion of existing product sales. 12-month target price: $25.